NEW YORK (GenomeWeb News) – RNAi services firm Cenix BioScience said today that it has extended an existing collaboration with CellCentric to validate epigenetic oncology drug candidates.

 

The new project follows a pilot study that the companies began in March under which Cenix used its RNAi-based phenotypic characterization platform to study several of CellCentric’s drug target candidates in a diverse panel of human cell lines.